Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials
Authors' conclusion
The treatment effect of semaglutide was statistically significant versus placebo and clinically relevant across all racial and ethnic subgroups in STEP 1 and 3 and STEP 2. All subgroups across both samples demonstrated good tolerability.
Study context
- Population
- Participants with obesity in the STEP 1, 2 and 3 trials, by racial and ethnic subgroups3 trials
- Comparison
- Once-weekly subcutaneous semaglutide 2.4 mg vs placebo
- Primary endpoint
- Estimated treatment difference in percent body weight change, semaglutide 2.4 mg vs placebo
Methodological detailsSTEP 1, 2 and 3, phase 3, subgroup analysis by race and ethnicity, STEP 1 and 3 pooled; STEP 2 examined separately
- STEP 1, 2 and 3
- Phase 3
- Subgroup analysis by race and ethnicity
- STEP 1 and 3 pooled; STEP 2 examined separately
Primary result
As reported in the abstract
Interaction between treatment effect and race or ethnicity (percent body weight change)
- Interaction between treatment effect and race, STEP 1 and 3 (not significant)
- p ≥ 0.07
- Interaction between treatment effect and race, STEP 2 (not significant)
- p ≥ 0.15
- Interaction between treatment effect and ethnicity, STEP 1 and 3 (not significant)
- p ≥ 0.40
- Interaction between treatment effect and ethnicity, STEP 2 (not significant)
- p ≥ 0.85
Further findings
Race and ethnicity of participants (STEP 1 and 3; STEP 2)
- White
- 75.3%; 59.4%
- Black
- 8.8%; 8.9%
- Asian
- 10.6%; 27.3%
- Other racial group
- 5.3%; 4.4%
- Hispanic or Latino
- 13.9%; 11.9%
- Not Hispanic or Latino
- 83.9%; 88.1%
Safety
- Safety of semaglutide 2.4 mg was consistent across subgroups
Original publication
Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials. Obesity (Silver Spring). Published 27 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →